港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

482.357

-14.363-2.89%

漲家數：12

跌家數：18

平家數：3

市盈率：- -

高：497.296

開：496.590

低：481.390

收：496.720

成交量：7,829.28萬

成交額：21.60億

市值：3,067.82億

流通市值：2,726.46億

資料載入中...

總覽新聞資訊

諾誠健華(09969)股價顯著上升14.18%，現價港幣$15.46

阿斯达克财经

港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化機構指回調後配置價值凸顯

大行評級丨高盛：上調中生製藥目標價至9.07港元，維持「買入」評級

大行評級丨花旗：維持康方生物「買入」評級，HARMONi-2總生存期優效強化ivonescimab差異化優勢

《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢

阿斯达克财经

康方生物(09926.HK)升近半成里昂：Harmoni-2總生存期更新正面

阿斯达克财经

港股異動 | 科濟藥業-B(02171)午前漲近3% FNC清淋預處理方案獲中國專利正式授權

《大行》野村：中生製藥(01177.HK)向大股東增購正大天晴5%股權市場認可交易戰略價值惟對估值存疑

阿斯达克财经

「超30家藥企長期行賄」，涉案醫院回應

港股異動丨康方生物漲近7%，依沃西試驗生存期超過默沙東競品

港股異動 | 諾誠健華(09969)升逾5% 近日PSMA/STEAP1雙抗ADC ICP-B381獲批臨床

康方生物港股走高其依沃西單藥在試驗中的總生存期超過默沙東競品

南方财经网

南新制藥（688189）被處罰，投資者索賠分析

康方生物(09926)出現大手賣出6.4萬股，成交價$90.0，涉資576萬

阿斯达克财经

康方生物盤初漲逾4% 依沃西對比帕博利珠單抗相關研究成果於WCLC大會重磅發布

港股異動 | 康方生物(09926.HK)高開逾4% 依沃西對比帕博利珠單抗相關研究成果於WCLC大會重磅發布

美國省錢、全球買單？行業研究警告：特朗普壓低藥價反成藥企海外漲價「激勵」

國家醫保局修訂印發2026版醫保服務協議範本

創新藥企赴港IPO提速小分子創新藥成主力賽道

经济参考报

B7-H3靶點ADC全球率先突破世界肺癌大會迎來中國時刻

中国新闻网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":482.35672,"timestamp":1789546124622,"preClose":496.71994,"halted":0,"volume":78292841,"delay":0,"changeRate":-0.028916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-14.36322,"latestTime":"09-16 16:00:00","open":496.59045,"high":497.2955,"low":481.3899,"amount":2159910416.1,"amplitude":0.032021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":3.69899,"peRate":164.598608,"turnoverRate":0.002939,"increases":11,"decrements":18,"flats":3,"marketCap":306781682880,"floatMarketCap":272645614616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":497.2955,"amplitude":0.032021,"preClose":496.71994,"low":481.3899,"pbRate":"3.69899","latestPrice":482.35672,"volume":78292841,"delay":0,"open":496.59045,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.388,"twentyDayClose":492.831,"sixtyDayClose":437.952,"secType":"PLATE","market":"HK","turnoverRate":0.002939,"peRate":164.598608,"marketCap":306781682880,"floatMarketCap":272645614616,"timestamp":1789546124622,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":18,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667302276","title":"諾誠健華(09969)股價顯著上升14.18%，現價港幣$15.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2667302276","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667302276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:45","pubTimestamp":1789364700,"startTime":"0","endTime":"0","summary":"[上升股]诺诚健华(09969) 股价在下午01:44比前收市价显著上升14.18%，现股价为港币$15.46。至目前为止，今日最高价为$15.46，而最低价为$13.38。总成交量为1.261千万股，总成交金额为港币$1.864亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141428/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141428/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","688428","09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上，9月12-15日，2026年世界肺癌大会召开，多项中国创新药临床数据集中亮相，康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出，WCLC集中披露的多项肺癌领域临床进展，进一步验证了中国创新药的临床价值和全球竞争力，或可积极把握创新药回调后的配置机会。机构普遍认为，三季度部分企业新增订单进入收入确认期，基本面有望持续改善。当前医药板块估值27倍PE，低于历史均值，回调后配置价值凸显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","KCAI","LU0634319403.HKD","06978","LU1961090484.USD","IBBQ","KURE","159992","BK4588","LU0348767384.USD","01177","LU0348735423.USD","LU0455707207.USD","LU2476274308.USD","LU0607220059.USD","BK1593","LU0348784397.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0417516738.SGD","01801","LU2097828805.USD","LU2097828714.EUR","HK0000165453.HKD","LU0348827113.USD","MEDX","LU2476274720.SGD","09969","LNGR","LU1831875114.USD","09926","LU0244354667.USD","LU1188198961.HKD","LU0348825331.USD","LU2097828557.USD","BK1574","LU0326950275.SGD","LU1969619763.USD","BK1191","LU0348766576.USD","01530","BK1161","IE00BZ08YR35.GBP","BK1521","LU2242644610.SGD","LU2778985437.USD","BK1589","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637715","title":"大行評級丨高盛：上調中生製藥目標價至9.07港元，維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637715","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637715?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:27","pubTimestamp":1789363638,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637732","title":"大行評級丨花旗：維持康方生物「買入」評級，HARMONi-2總生存期優效強化ivonescimab差異化優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637732","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637732?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:24","pubTimestamp":1789363448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09926","IE00B5MMRT66.SGD","LU0634319403.HKD","KURE","LU0561508036.HKD","LU0348735423.USD","LU0540923850.HKD","LU2488822045.USD","IE00B543WZ88.USD","LU0348784397.USD","LU0348827113.USD","LU2476274720.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","BK1574","LU2476274308.USD","LU0417516902.SGD","LU0348767384.USD","LU0348825331.USD","LU0417516571.SGD","LU0417516738.SGD","BK1161","LU2778985437.USD","LU0348766576.USD","LU1720050803.USD","LU0348783233.USD","LU2399975544.HKD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632069","title":"《大行》花旗：康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632069","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632069?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 12:14","pubTimestamp":1789359240,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指，康方生物的HARMONi-2中期读数显示，ivonescimab作为PD-L1阳性非小细胞肺癌一线单药治疗，对比pembrolizumab展现有意义的总生存期优效，强化其差异化定位，全球读数仍是关键。该行指出，HARMONi-2在234宗总生存期事件下，ivonescimab的中位总生存期为30.75个月；总生存期获益在PD-L1 TPS > 50%及鳞状非小细胞肺癌，整体存活期获益最为明显，安全性大致相若。该行维持康方生物“买入”评级，目标价171港元不变。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09926","LU1720050803.USD","LU2399975544.HKD","LU0348827113.USD","LU2476274308.USD","LU0348766576.USD","LU0417516738.SGD","LU1961090484.USD","LU0540923850.HKD","BK1574","LU0561508036.HKD","LU2778985437.USD","LU0417516902.SGD","LU2488822045.USD","LU0348767384.USD","BK1161","LU2476274720.SGD","LU0348825331.USD","LU0634319403.HKD","LU0348783233.USD","LU0348784397.USD","IE00BPRC5H50.USD","KURE","IE00B5MMRT66.SGD","LU1794554557.SGD","LU0417516571.SGD","IE00B543WZ88.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632490","title":"康方生物(09926.HK)升近半成  里昂：Harmoni-2總生存期更新正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632490","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632490?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:57","pubTimestamp":1789358220,"startTime":"0","endTime":"0","summary":"康方生物今日高开4.49%，最高见96.55元。里昂发表研究报告指，康方生物公布Harmoni-2正面总生存期更新，ivonescimab录得中位OS 30.75个月，对比pembrolizumab 22.57个月，风险比为0.73，显示具统计学意义及临床意义的生存获益。该行认为，该药OS结果符合投资者预期，并为医生提供更多ivonescimab临床表现优于pembrolizumab的证据，尽管风险比不及Harmoni-6的0.66更新吸引；OS数据亦较2025年4月中国标签更新时风险比0.78有所改善。Harmoni-3无进展生存期读出，以及美国FDA于今年下半年就ivonescimab的决定，为后续关键催化剂。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544272/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544272/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1961090484.USD","LU0348827113.USD","09926","LU0348767384.USD","IE00BPRC5H50.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU0634319403.HKD","LU2399975544.HKD","IE00B543WZ88.USD","LU2488822045.USD","LU1720050803.USD","LU0348784397.USD","LU0561508036.HKD","LU0348825331.USD","LU0348735423.USD","LU2778985437.USD","BK1161","LU1794554557.SGD","LU2476274720.SGD","LU0417516738.SGD","LU0417516571.SGD","LU0348783233.USD","LU0348766576.USD","LU2476274308.USD","BK1574","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667321696","title":"港股異動 | 科濟藥業-B(02171)午前漲近3% FNC清淋預處理方案獲中國專利正式授權","url":"https://stock-news.laohu8.com/highlight/detail?id=2667321696","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667321696?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:54","pubTimestamp":1789358057,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B午前涨近3%，截至发稿，涨2.47%，报12.86港元，成交额1644.03万港元。消息面上，9月14日，据科济药业官微消息，公司自主研发的FNC清淋预处理方案正式获得中国国家知识产权局专利授权。此次FNC清淋预处理方案在中国获得专利授权，意味着公司对恺力美的保护已从单一产品层面，延伸至涵盖清淋预处理在内的整体治疗方案层面，提升了同类竞品的研发与商业化门槛，进一步巩固了公司在实体瘤CAR-T领域的领先地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","VXUS","02171","BK1587","BK1161","KCAI","BK4585","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632971","title":"《大行》野村：中生製藥(01177.HK)向大股東增購正大天晴5%股權  市場認可交易戰略價值惟對估值存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632971","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632971?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:51","pubTimestamp":1789357860,"startTime":"0","endTime":"0","summary":"野村发表报告指，中生制药将以现金约44.8亿元人民币，向执行董事兼主要股东谢承润增购非上市附属公司正大天晴额外5%股权，交易按正大天晴股权估值896亿元人民币计算，完成后，中生制药持股将由60%升至65%。野村维持对中生制药“买入”评级，目标价8.67元。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544269/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544269/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1521","01177","BK1589","IE00BZ08YT58.USD","BK1574","01477","BK1515","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863208","title":"「超30家藥企長期行賄」，涉案醫院回應","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863208","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:36","pubTimestamp":1789356960,"startTime":"0","endTime":"0","summary":"澎湃新闻首席记者 李潇潇9月13日，国家医保局发布《医疗机构涉医药购销商业贿赂案》一文提到，仅2025年下半年，河北医科大学第二医院就涉及9件司法刑事判决。在国家医保局9月13日最新披露的信息中，有超过30家医药企业长期对河北医科大学第二医院工作人员行贿。具体到河北祥恩医疗器械贸易有限公司一家，该公司为向河北医科大学第二医院销售价格虚高的医疗耗材，累计向该医院工作人员行贿2064万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","MDEV","AGNG","IEIH","PTH","RSPH","09996","BK1100","GDOC","HART","LNGR","BK1583","BK1574","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632842","title":"港股異動丨康方生物漲近7%，依沃西試驗生存期超過默沙東競品","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632842","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632842?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:33","pubTimestamp":1789356838,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2476274720.SGD","LU0634319403.HKD","LU2399975544.HKD","LU1720050803.USD","09926","LU0540923850.HKD","LU2476274308.USD","LU0348825331.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0417516902.SGD","LU1794554557.SGD","BK1574","LU0348783233.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU0348784397.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0561508036.HKD","KURE","BK1161","LU0417516738.SGD","LU0348735423.USD","LU0417516571.SGD","LU1961090484.USD","LU0348766576.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667763485","title":"港股異動 | 諾誠健華(09969)升逾5% 近日PSMA/STEAP1雙抗ADC ICP-B381獲批臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667763485","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667763485?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:30","pubTimestamp":1789353028,"startTime":"0","endTime":"0","summary":"消息面上，据诺诚健华官微消息，近日，公司自主研发的靶向PSMA和STEAP1的双抗ADC新药ICP-B381获国家药品监督管理局药品审评中心批准开展临床试验，用于治疗前列腺癌等实体瘤。目前，全球尚无靶向PSMA和STEAP1的双抗ADC获批上市。ICP-B381是诺诚健华基于自主研发ADC平台开发的首个双抗ADC，由人源化抗PSMA/STEAP1抗体、公司自主研发的新一代不可逆连接子和强效有效载荷偶联而成。同等给药剂量下，药效优于对应的单靶点 PSMAADC和STEAP1ADC，且耐受性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495472.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688428","BK4585","KCAI","VXUS","BK4588","09969","BK1574","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667463107","title":"康方生物港股走高 其依沃西單藥在試驗中的總生存期超過默沙東競品","url":"https://stock-news.laohu8.com/highlight/detail?id=2667463107","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667463107?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:16","pubTimestamp":1789352160,"startTime":"0","endTime":"0","summary":"南方财经9月14日电，康方生物港股盘初一度上涨5.8%，随后收窄涨幅。此前公司宣布，对比默沙东公司的帕博利珠单抗，其肿瘤免疫药物依沃西显著延长了中位总生存期(OS)至30.8个月，而前者为22.6个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873200884.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873200884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348735423.USD","LU0348767384.USD","LU2476274720.SGD","LU2476274308.USD","BK1161","LU0561508036.HKD","LU1794554557.SGD","KURE","LU1961090484.USD","LU0348784397.USD","LU0348766576.USD","BK1574","LU2399975544.HKD","IE00B543WZ88.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348783233.USD","LU2488822045.USD","LU2778985437.USD","VXUS","LU1720050803.USD","IE00BPRC5H50.USD","BK4588","LU0417516571.SGD","KCAI","LU0348825331.USD","LU0540923850.HKD","LU0417516902.SGD","LU0348827113.USD","IE00B5MMRT66.SGD","09926","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631739","title":"南新制藥（688189）被處罰，投資者索賠分析","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631739","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631739?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:59","pubTimestamp":1789351140,"startTime":"0","endTime":"0","summary":"部分股民或许存在索赔机会。徐劲律师认为，根据证券虚假陈述新司法解释，已明确取消前置程序，投资者因上市公司虚假陈述导致损失，可以向有管辖权的法院提起民事赔偿诉讼以维护自己的合法权益，可索赔损失范围包括投资差额损失、印花税及佣金损失。暂定索赔条件：在2024年3月26日到2025年9月30日期间买入，并且在2025年9月30号后卖出或仍持有而亏损的投资者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/gmwq/rightscase/2026-09-14/doc-iniruara9679607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","688189","BK0239","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863165","title":"康方生物(09926)出現大手賣出6.4萬股，成交價$90.0，涉資576萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863165","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863165?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:45","pubTimestamp":1789350300,"startTime":"0","endTime":"0","summary":"[大手成交]康方生物(09926)在上午09:45出现大手卖出，成交量为6.4万，成交价为港币$90.0，涉资576万。至目前为止，股价跌0.166%，今日最高价为$95.5，而最低价为$90.0，总成交量为364.9万股，总成交金额港币$3.343亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132515779_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609142177/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609142177/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2778985437.USD","BK1574","LU0348735423.USD","KURE","LU0417516571.SGD","LU0417516738.SGD","LU0348825331.USD","LU2476274308.USD","LU0348783233.USD","LU0561508036.HKD","LU0348784397.USD","LU0417516902.SGD","LU2488822045.USD","09926","BK1161","LU0634319403.HKD","LU2399975544.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0348827113.USD","LU1961090484.USD","IE00BPRC5H50.USD","LU2476274720.SGD","LU1720050803.USD","LU1794554557.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631397","title":"康方生物盤初漲逾4% 依沃西對比帕博利珠單抗相關研究成果於WCLC大會重磅發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631397","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631397?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:44","pubTimestamp":1789350240,"startTime":"0","endTime":"0","summary":"据康方生物官微消息，在国际肺癌研究协会主办的2026年世界肺癌大会上，公司全球首创肿瘤免疫2.0基石药物依沃西，对比帕博利珠单抗，一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的随机、双盲、对照、多中心、注册性III期临床研究的OS显著阳性结果重磅发布。截至目前，依沃西在多项头对头对比PD-1/L1疗法的III期临床中取得OS和PFS双阳性结果，并逐步拓展至肺癌以外的重大实体瘤领域。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-14/doc-iniruara9666421.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B5MMRT66.SGD","BK1161","LU2476274720.SGD","LU0348825331.USD","LU0348827113.USD","IE00BPRC5H50.USD","LU0348766576.USD","LU0561508036.HKD","LU0348767384.USD","KURE","LU2399975544.HKD","LU0417516738.SGD","LU0348784397.USD","IE00B543WZ88.USD","LU0348735423.USD","LU0417516571.SGD","LU0348783233.USD","LU2488822045.USD","LU2476274308.USD","LU2778985437.USD","LU0417516902.SGD","LU0634319403.HKD","LU1720050803.USD","09926","LU1794554557.SGD","LU0540923850.HKD","BK1574","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667639745","title":"港股異動 | 康方生物(09926.HK)高開逾4% 依沃西對比帕博利珠單抗相關研究成果於WCLC大會重磅發布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667639745","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667639745?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:28","pubTimestamp":1789349287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KURE","LU0417516902.SGD","LU0634319403.HKD","LU0348766576.USD","LU0348767384.USD","LU2778985437.USD","LU0417516571.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348735423.USD","LU0348784397.USD","LU0348825331.USD","LU2476274308.USD","BK1574","LU0348827113.USD","LU0348783233.USD","LU0417516738.SGD","BK1161","IE00BPRC5H50.USD","LU2476274720.SGD","LU2399975544.HKD","IE00B5MMRT66.SGD","LU1961090484.USD","LU2488822045.USD","LU1720050803.USD","09926","LU0540923850.HKD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667636119","title":"美國省錢、全球買單？行業研究警告：特朗普壓低藥價反成藥企海外漲價「激勵」","url":"https://stock-news.laohu8.com/highlight/detail?id=2667636119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667636119?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 08:30","pubTimestamp":1789345800,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，一项研究发现，特朗普政府推动降低美国药品支出的举措，反而构成了一种强有力的激励，促使制药公司提高药价并减少世界其他地区的药品可及性。这位总统希望美国联邦医疗保险这一联邦医保计划中的药价，能与其他富裕国家的药价看齐。制药公司已与白宫达成了一系列协议，同时一些公司也在寻求利用美国这一政策作为杠杆，在别处抬价。但如果与白宫单独达成定价协议的 17 家公司获得豁免，这一数字将缩水至 33 亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667636378","title":"國家醫保局修訂印發2026版醫保服務協議範本","url":"https://stock-news.laohu8.com/highlight/detail?id=2667636378","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667636378?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 08:11","pubTimestamp":1789344663,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1515","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635798","title":"創新藥企赴港IPO提速 小分子創新藥成主力賽道","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635798","media":"经济参考报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635798?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 07:52","pubTimestamp":1789343542,"startTime":"0","endTime":"0","summary":"【创新药企赴港IPO提速 小分子创新药成主力赛道】8月下旬以来，征祥医药、益方生物、迪哲医药、贝达药业、维眸生物、诺令生物、普莱医药、信立泰等多家企业，密集向港交所递交上市申请，掀起新一轮本土创新药闯关港股18A板块的热潮。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202609143872918250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["LNGR","MEDX","KCE","159992","06978","FRHC","IBBQ","IPOS","BK1161","BK4127","BK1574","REDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667682589","title":"B7-H3靶點ADC全球率先突破 世界肺癌大會迎來中國時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2667682589","media":"中国新闻网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667682589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 20:11","pubTimestamp":1789301465,"startTime":"0","endTime":"0","summary":"9月13日，韩国首尔，世界肺癌大会(WCLC)主席论坛。中山大学肿瘤防治中心张力教授分享了B7-H3抗体偶联药物依康坦博妥塔单抗(Tam-Peli，代号YL201)对比盐酸托泊替康用于治疗复发性小细胞肺癌的Ⅲ期注册研究TAISHAN-302成果，这是全球范围内以B7-H3为靶点的ADC首次公布Ⅲ期临床研究数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609133872861815.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609133872861815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","IBBQ","BK1161","MEDX","LNGR","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":5,"totalSize":329,"code":"91000000","status":"200"}]}}